Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Liver Neoplasms 3Cholangiocarcinoma 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 2Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 27Cisplatin 24pembrolizumab 15durvalumab 12Fluorouracil 11Capecitabine 10Oxaliplatin 9Leucovorin 8Bevacizumab 7Carboplatin 5Paclitaxel 4Nivolumab 4Irinotecan 4Injections 4zanidatamab 3trametinib 3lenvatinib 3derazantinib 3atezolizumab 3Ramucirumab 3Docetaxel 3tremelimumab 2surufatinib 2pertuzumab 2gemcitabine-oxaliplatin regimen 2envafolimab 2Trastuzumab 2S 1 (combination) 2Itraconazole 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × derazantinib × Clear all
NCT04087876 2025-04-06

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Basilea Pharmaceutica

No longer available
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03230318 2023-12-19

FIDES-01

Basilea Pharmaceutica

Phase 2 Completed
148 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT01752920 2023-06-05

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Basilea Pharmaceutica

Phase 1/2 Completed
119 enrolled 15 charts
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡